Compare MAC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAC | RYTM |
|---|---|---|
| Founded | 1964 | 2008 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.3B |
| IPO Year | 1994 | 2017 |
| Metric | MAC | RYTM |
|---|---|---|
| Price | $24.06 | $116.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 19 |
| Target Price | $26.87 | ★ $140.12 |
| AVG Volume (30 Days) | ★ 2.7M | 1.6M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | 11.36 | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,013,983,000.00 | N/A |
| Revenue This Year | N/A | $74.20 |
| Revenue Next Year | $8.59 | $74.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $16.03 | $74.50 |
| 52 Week High | $26.68 | $122.20 |
| Indicator | MAC | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 62.72 |
| Support Level | $23.16 | $82.31 |
| Resistance Level | $25.96 | $119.75 |
| Average True Range (ATR) | 0.59 | 7.90 |
| MACD | -0.09 | 1.52 |
| Stochastic Oscillator | 9.00 | 94.01 |
Macerich invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and nine regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $199 in sales per square foot over the 12 months ended in June 2026.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.